Skip to main content

Drug Safety

      Do pts w autoimmune disease (AID) respond differently to immune checkpoint inhibitors (ICI) & have different mortali
      1 month ago
      Do pts w autoimmune disease (AID) respond differently to immune checkpoint inhibitors (ICI) & have different mortality or iRAE risk vs pts without AID? Study of pts on ICI showed no significant difference in mortality in pts w & without pre-existing AID Ab2532 #ACR24 @RheumNow https://t.co/suywDdGIB1
      Overall very reasonable, aligning ACR recs w/other guidance groups & updated data

      Remember: guidelines are meant to
      1 month ago
      Overall very reasonable, aligning ACR recs w/other guidance groups & updated data Remember: guidelines are meant to be broken. Some patients can likely avoid pulse, others may need more steroid on the back end, biopsies are not benign #ACR24 @RheumNow
      Recommend "Triple Therapy" = Glucocorticoids + two other agents

      Practically, that means MMF + belimumumab OR CNI for m
      1 month ago
      Recommend "Triple Therapy" = Glucocorticoids + two other agents Practically, that means MMF + belimumumab OR CNI for most pts For the CYC afficionados, the lower-dose EUROLUPUS protocol is preferred #ACR24 @RheumNow https://t.co/0gRISXSw0c
      Happening now, new guidelines for mgmt. A few highlights:

      Recommend prompt GC therapy, pulse x1-3d followed by oral pr
      1 month ago
      Happening now, new guidelines for mgmt. A few highlights: Recommend prompt GC therapy, pulse x1-3d followed by oral pred (<0.5mg/kg/d) w/taper to <5mg by 6 months Aligns with EULAR recs for a much-lower dose than most clinicians currently doing #ACR24 @RheumNow https://t.co/B71i7FBYlQ
      Abstract 2503: Clofutriben (HSD-1 inhibitor) minimizes adrenal suppression. Adding clofutriben to prednisolone boosts A
      Abstract 2503: Clofutriben (HSD-1 inhibitor) minimizes adrenal suppression. Adding clofutriben to prednisolone boosts ACTH & cortisol levels with fewer patients with suppressed morning cortisol (≤5.0 mg/dL) (34% vs 14%). @RheumNow #ACR24 #GCTox
      Low uveitis rates in patients with axial spondyloarthritis and psoriatic arthritis treated with bimekizumab (BKZ) over t
      Low uveitis rates in patients with axial spondyloarthritis and psoriatic arthritis treated with bimekizumab (BKZ) over the long term. Key findings: - AxSpA: 3.7% incidence (1.3/100 PY) with BKZ. - PsA: Only 0.2% incidence (0.1/100 PY). - All events were mild/moderate, with no… https://t.co/jkUwHJk3FJ https://t.co/gTcCzeC88e
      Hyrich:
      ETN originator vs biosimilar initiation
      - DAS28 - no signif change at B/L, 6mo, 12 mo.

      Switch?
      Matched pts in E
      1 month ago
      Hyrich: ETN originator vs biosimilar initiation - DAS28 - no signif change at B/L, 6mo, 12 mo. Switch? Matched pts in ETN switch v cont originator - good b/l control on Rx -DAS28 maintained w switch 10% did go back to originator, felt less good tho similar DAS #ACR24 @RheumNow https://t.co/RHRit5CtUu
      Early observational data suggesting JAK inhibitors can play a role in TAK tx

      We have seen this with UPA in GCA this con
      Early observational data suggesting JAK inhibitors can play a role in TAK tx We have seen this with UPA in GCA this conference… time for SELECT-TAK ! @RheumNow #ACR24 https://t.co/B2Wa8sOFTp
      Using longitudinal claims data, this study explores the safety of non-conventional combination targeted therapy in adult
      Using longitudinal claims data, this study explores the safety of non-conventional combination targeted therapy in adults with psoriatic arthritis (PsA). Key findings: - 42,821 PsA patients analyzed; only 1.1% on combination therapy. - Increased risk of serious infections:… https://t.co/Jghmz9lkLd https://t.co/YqwJlTKcEi
      The findings from ORAL Surveillance Study have been a dominant conversation at recent ACR Convergence, with the seminal findings and subsequent analyses a target of debate. This study comparing the…
      ×